AR050691A1 - Compuestos de isoindolona como potenciadores del receptor metabotropico de glutamato. procesos de obtencion y composiciones farmaceuticas. - Google Patents

Compuestos de isoindolona como potenciadores del receptor metabotropico de glutamato. procesos de obtencion y composiciones farmaceuticas.

Info

Publication number
AR050691A1
AR050691A1 ARP050103330A ARP050103330A AR050691A1 AR 050691 A1 AR050691 A1 AR 050691A1 AR P050103330 A ARP050103330 A AR P050103330A AR P050103330 A ARP050103330 A AR P050103330A AR 050691 A1 AR050691 A1 AR 050691A1
Authority
AR
Argentina
Prior art keywords
alkyl
dihydro
isoindol
nr10r11
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP050103330A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NPS Pharmaceuticals Inc
AstraZeneca AB
Original Assignee
NPS Pharmaceuticals Inc
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35428151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050691(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NPS Pharmaceuticals Inc, AstraZeneca AB filed Critical NPS Pharmaceuticals Inc
Publication of AR050691A1 publication Critical patent/AR050691A1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos pertenecen a la categoría de isoindolonas utilizados como potenciadores del receptor metabotropico de glutamato. Procedimiento de obtencion de los mismos. Composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) en donde: R1 es un anillo de 3 a 7 miembros que puede contener uno o más heteroátomos seleccionados en forma independiente del grupo formado por N, O y S, en donde dicho anillo puede estar sustituido por uno o más A; R2 y R3 se seleccionan en forma independiente del grupo formado por H, C1-6-alquilo, C2-6- alquenilo, C2-6-alquinilo, arilo, heteroarilo, heterocicloalquilo, C3-8-cicloalquilo, C1-6-alquil-arilo, C1-6-alquil-heteroarilo, C1-6-alquil- heterocicloalquilo, y C1-6-alquil-cicloalquilo, en donde R2 y R3 pude estar sustituido con uno o más A; R4 y R6 se seleccionan en forma independiente del grupo formado por H, hidroxi, F, Cl, Br, I, nitro, ciano, C1-6-alquilo, C1-6-alquilhalo, OC1- 6alquilo, OC1-6-alquilhalo, C2-6-alquenilo, OC2-6-alquenilo, C2-6-alquinilo, OC2-6-alquinilo, C3-8-cicloalquilo, C1-6-alquil-C3-8-cicloalquilo, OC0-6-alquil-C3-8-cicloalquilo, arilo, C1-6-alquilarilo, OC0-6-alquilarilo, (CO)R10, O(CO)R10, O(CO)OR10, C(O)OR10, O(CNR10)OR11, C1-6-alquilOR10, OC2-6alquilOR10, C1-6-alquil(CO)R10, OC1-6- alquil(CO)R10, C0-6-alquilCO2R10, OC1-6-alquilCO2R10, C1-6-alquilciano, OC2-6-alquilciano, C0-6-alquilNR10R11, OC2-6-alquilNR10R11, C1-6- alquil(CO)NR10R11, OC1-6- alquil(CO)NR10R11, C0-6-alquiNR10(CO)R11, OC2-6-alquilNR10(CO)R11, C0-6-alquilNR10(CO)NR10R11, C0-6-alquilSR10, OC2-6-alquilSR10, C0-6-alquil(SO)R10, OC2-6-alquil(SO)R10, C0-6-alquilSO2R10, OC2-6-alquilSO2R10, C0-6-alquil(SO2) NR10R11, C0-6- alquilNR10(SO2)R11, OC2-6-alquilNR10(SO2)R11, C0-6-alquilNR10(SO2)NR10R11, OC2-6-alquilNR10(SO2)NR10R11, (CO)NR10R11, O(CO)NR10R11, NR10OR11, C0-6-alquilNR10(CO)OR11, OC2-6-alquilNR10(CO)OR11, SO3R10 y un anillo de 5 a 7 miembros que puede contener uno o más heteroátomos seleccionados en forma independiente del grupo formado por N, O y S, en donde R4 y R6 puede estar sustituido con uno o más A, y en donde cualquier cicloalquilo o arilo puede estar opcionalmente fusionado a un anillo de 5 a 7 miembros que puede contener uno o más heteroátomos seleccionados en forma independiente del grupo formado por C, N, O y S; R5 se selecciona del grupo formado por H, F, Cl, Br, I, nitro, C1-6- alquilo, C1-6-alquilhalo, OC1-6-alquilhalo, C2-6- alquenilo, OC2-6-alquenilo, C2-6-alquinilo, OC2-6-alquinilo, C3-8-cicloalquilo, C1-6-alquil-C3-8-cicloalquilo, OC0-6-alquil-C3-8-cicloalquilo, arilo, C1-6-alquilarilo, C1-6-alquilheteroarilo, OC1-6-alquilarilo, OC1-6-alquilheteroarilo, C1-6- alquilheterocicloalquilo, Oheterocicloalquilo, OC1-6-alquilheterocicloalquilo, C(O)H, (CO)R10, O(CO)R10, O(CO)OR10, C(O)OR10, O(CN)OR10, C1-6-alquilOR10, OC2-6-alquilOR10, C1-6-alquil(CO)R10, OC1-6-alquil(CO)R10, C0-6-alquilCO2R10, C1-6-alquilciano, OC2-6-alquilciano, C0-6-alquilNR10R11, OC2-6-alquilNR10R11, C1-6-alquil(CO)NR10R11, OC1-6-alquil(CO)NR10R11, C0-6-alquilNR10(CO)R11, OC2-6-alquuilNR10(CO)R11, C0-6-alquilNR10(CO)NR10R11, C0-6-alquilSR10, OC2-6-alquilSR10, C0-6-alquil(SO)R10, OC2-6- alquil(SO)R10, C0-6-alquilSO2R10, OC2-6-alquilSO2R10, C0-6-alquil(SO2)NR10R11, OC2-6-alquil(SO2)NR10R11, C0-6-alquilNR10(SO2)R11, OC2-6-alquilNR10(SO2)R11, C0-6-alquilNR10(SO2)NR10R11, OC2-6-alquilNR10(SO2)NR10R11, (CO)NR10R11, O(CO)NR10R11, NR10R11, C0-6-alquilNR10(CO)OR11, OC2-6-alquilNR10(CO)OR11, SO3R10 y un anillo de 5 a 7 miembros que puede contener uno o más heteroátomos seleccionados en forma independiente del grupo formado por N, O y S, en donde R5 puede estar sustituido co uno o más A, y en donde cualquier porcion cíclica puede estar opcionalmente fusionada con un anillo de 5 a 7 miembros que puede contener uno o más heteroátomos seleccionados en forma independiente del grupo formado por C, N, O y S; R7 se selecciona del grupo formado por H, F, Cl, Br, I, nitro, ciano, OC1-4-alquilo, C1-6-alquilo, C1-6-alquilhalo, OC1-6-alquilhalo, C2-6-alquenilo, OC2-6-alquenilo, C2-6-alquinilo, OC2-6-alquinilo, y C3-8-cicloalquilo; R8 y R9 se seleccionan en forma independiente del grupo formado por H, F, Cl, Br, I, nitro, ciano, C1-6-alquilo, C1-6-alquilhalo, OC1-6alquilo, OC1-6-alquilhalo, C2-6-alquenilo, OC2-6-alquenilo, C2-6-alquinilo, y OC2-6-alquinilo, o cuando n es mayor que |1, dos o más R8 y/o R9 en átomos de carbono contiguos pueden estar ausentes para formar una porcion alquenilo o alquinilo; R10 y r11 se seleccionan en forma independiente del grupo formado por H, hidroxi, oxo, F, Cl, Br, I, nitro, ciano, C1-6- alquilo, C1-6-alquilhalo, OC1-6alquilo, OC1-6- alquilhalo, C2-6-alquenilo, OC2-6-alquenilo, C2-6-alquinilo, OC2-6-alquinilo, C3-8-cicloalquilo, C1-6-alquil-C3-8-cicloalquilo, OC0-6-alquil-C3-8-cicloalquilo, arilo, C1-6-alquilarilo, OC0-6-alquilarilo, C0-6-alquil-heterocicloalquilo, OC1-6-alquil- heterocicloalquilo, heteroarilo, y C1-6alquilheteroarilo, en donde cualquier porcion cíclica puede estar opcionalmente fusionada con un anillo de 5 a 7 miembros que puede contener uno o más heteroátomos seleccionados en forma independiente del grupo formado por C, N, O y S y cualquier porcion cíclica está opcionalmente sustituida con un sustituyente seleccionado entre alquilo, halo, hidroxilo, Oalquilo, haloalquilo y Ohaloalquilo; A se selecciona del grupo formado por H, hidroxi, F, Cl, Br, I, nitro, ciano, oxo, C1-6- alquilo, C1-6-alquilhalo, OC1-6alquilo, OC1-6-alquilhalo, C2-6-alquenilo, OC2-6-alquenilo, C2-6-alquinilo, OC2-6-alquinilo, C3-8-cicloalquilo, C1-6-alquil-C3-8-cicloalquilo, OC0-6-alquil-C3-8-cicloalquilo, arilo, C1-6- alquilarilo, OC0-6-alquilarilo, C1-6-alquil-heterociclilo, C1-6-alquil-heterocicloalquilo, OC0-6-alquil-heterocicloalquilo, (CO)R10, O(CO)R10, O(CO)OR10, O(CNR10)OR11, C1-6-alquilOR10, OC2-6alquilOR10, C1-6-alquil(CO)R10, OC1-6- alquil(CO)R10, C0-6- alquilCO2R10, OC1-6-alquilCO2R10, C1-6-alquilciano, OC2-6-alquilciano, C0-6-alquilNR10R11, OC2-6-alquilNR10R11, C0-6-alquil(CO)NR10R11, OC1-6-alquil(CO)NR10R11, C0-6-alquiNR10(CO)R11, OC2-6-alquilNR10(CO)R11, C0-6-alquilNR10(CO)NR10R11, C0-6- alquilSR10, OC2-6-alquilSR10, C0-6-alquil(SO)R10, OC2-6-alquil(SO)R10, C1-6-alquilSO2R10, OC2-6-alquilSO2R10, C0-6-alquil(SO2) NR10R11, OC2-6-alquil(SO2)NR10R11, C0-6-alquilNR10(SO2)R11, OC2-6-alquilNR10(SO2)R11,C0-6-alquilNR10(SO2)NR10R11, OC2-6- alquilNR10(SO2)NR10R11, (CO)NR10R11, O (CO)NR10R11, NR10OR11, C0-6-alquilNR10(CO)OR11, OC2-6-alquilNR10(CO)OR11, SO3R10 y un anillo de 5 a 7 miembros que puede contener uno o más heteroátomos seleccionados en forma independiente del grupo formado por N, O y S, en donde dicho anillo de 5 a 7 miembros está opcionalmente sustituido con uno o más de R10 y R11; y n se selecciona del grupo formado por 1, 2, 3, 4, 5, 6, 7, y 8; o una sal aceptable para uso farmacéutico, hidrato, solvato, isomero optico o combinacion de los mismos; con la salvedad de que el compuesto no sea: 1,1-dimetiletiléster del ácido 4-[(5-bromo-1,3-dihidro-1-oxo-2H-isoindol-2-il)metil]-1-piperidincarboxílico, 5-bromo-2,3-dihidro-2-(4-piperidinilmetil)-1H-isoindol-1- ona, ácido 4-[(5-cloro-1,3-dihidro-1-oxo-2H-isoindol-2-il)metil]-1-piperidincarboxílico, 5-cloro-2,3-dihidro-2-(4-piperidinilmetil)-1H-isoindol-1-ona, 1,1-dimetiletiléster del ácido 4-[(1,3-dihidro-5-metoxi-1-oxo-2H-isoindol-2-il)metil]-1- piperidincarboxílico, 2,3-dihidro-5-metoxi-2-(4-piperidinilmetil)-1H-isoindol-1-ona, 1,1-dimetiletiléster del ácido 4-[(5-ciano-1,3-dihidro-1-oxo-2H-isoindol-2-il)metil]-1-piperidincarboxílico, 2,3-dihidro-1-oxo-2-(4-piperidinilmetil)-1H-isoindol-5- carbonitrilo, 1,1-dimetiletiléster del ácido 4-[(5-fluoro-1,3-dihidro-1-oxo-2H-isoindol-2-il)metil]-1-piperidincarboxílico, 5-fluoro-2,3-dihidro-2-(4-piperidinilmetil)-1H-isoindol-1-ona, 2,3-dihidro-5-(metoximetil)-2-(fenilmetil)-1H-isoindol-1-ona, 2,3-dihidro-5-hidroxi-2-[2-(4-morfolinil)etil]-1H-isoindol-1-ona, 2-[[(2R)-4,4-dietoxi-1-[(1S)-1-feniletil]-2-piperidinil]metil]-2,3-dihidro-7-metoxi-1H-isoindol-1-ona, 2,3-dihidro-7-metoxi-2-[[(2R)-4-oxo-[(1S)-1-feniletil]-2-piperidinil]metil]-1H- isoindol-1-ona, [[7-cloro-2,3-dihidro-1-oxo-2-(fenilmetil)-1-H-isoindol-5-il]oxi]-acético ácido, etiléster del ácido [[7-cloro-2,3-dihidro-1-oxo-2-(fenilmetil)-1H-isoindol-5-il]oxi]-acético, 5-fluoro-2,3-dihidro-2-[3-[4-(2-metoxifenil)-1- piperazinil]propil]-1H-isoindol-1-ona, etiléster del ácido [[2,3-dihidro-2-[2-(4-morfolinil)etil]1-oxo-1H-isoindol-5-il]oxi]acético, etil-(2-bencil-3-oxo-2,3-dihidro-1H-isoindol-1-il)-acetato, etil-(2-ciclopropilmetil-3-oxo-2,3-dihidro-1H-isoindol-1- il)-acetato, ácido (5-fenoximetil-2-(1-fenil-3-metil-butil)-3-oxo-2,3-dihidro-1H-isoindol-1-il)-acético, 5,6-dimetoxi-1-oxo-N-2-(4-(2-metoxifenil)-1-piperazinil)etil-isoindol, 5,6-dimetoxi-1-(3,4-dimetoxi)bencil-3-oxo-2-(4-(2-metoxifenil)-1- piperazinil)etil-isoindol, 2,3-dihidro-3-alil-3-hidroxi-2-bencil-1H-isoindol-1-ona, 2,3-dihidro-2-bencil-3-metil-1H-isoindol-1-ona, 2,3-dihidro-2,3-dibencil-1H-isoindol-1-ona, 2-3-dihidro-3-alil-2-bencil-1H-isoindol-1-ona, 2,3-dihidro-2-bencil-3-((1- hidroxi)butil-3-metil-1H-isoindol-1-ona, 2,3-dihidro-2-bencil-3-((1-hidroxi-1-metil)etil)-3-metil-1H-isoindol-1-ona, metil-(2,3-dihidro-3-metil-3-oxo-2-bencil-1H-isoindol-1-il)-acetato, metil-(2,3-dihidro-3-fenil-3-oxo-2-bencil-1H-isoindol-1-il)- acetato, metil-(2,3-dihidro-3-(furan-2-il)-3-oxo-2-bencil-1H-isoindol-1-il)-acetato, metil-(2,3-dihidro-3-metil-3-oxo-2-((2-fenil)etil)-1H-isoindol-1-il)-acetato, metil-(2,3-dihidro-3-fenil-3-oxo-2-((2-fenil)etil)-1H-isoindol-1-il)-acetato, metil- (2,3-dihidro-3-(furan-2-il)--3-oxo-2-((2-fenil)etil)-1H-isoindol-1-il)-acetato, 2,3-dihidro-3-fenil-2,3-dibencil-1H-isoindol-1-ona, 2,3-dihidro-2,3,3-tribencil-1H-isoindol-1-ona, 2,3-dihidro-2,3-dibencil-1H-isoindol-1-ona o 2,3-dihidro-3,3-dimetil-2- bencil-1H-isoindol-1-ona.
ARP050103330A 2004-08-13 2005-08-11 Compuestos de isoindolona como potenciadores del receptor metabotropico de glutamato. procesos de obtencion y composiciones farmaceuticas. Pending AR050691A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60112504P 2004-08-13 2004-08-13
US68494505P 2005-05-27 2005-05-27

Publications (1)

Publication Number Publication Date
AR050691A1 true AR050691A1 (es) 2006-11-15

Family

ID=35428151

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103330A Pending AR050691A1 (es) 2004-08-13 2005-08-11 Compuestos de isoindolona como potenciadores del receptor metabotropico de glutamato. procesos de obtencion y composiciones farmaceuticas.

Country Status (16)

Country Link
US (1) US7968570B2 (es)
EP (2) EP1778634A1 (es)
JP (2) JP5031565B2 (es)
KR (3) KR20140116208A (es)
CN (2) CN101039907B (es)
AR (1) AR050691A1 (es)
AU (1) AU2005272738B2 (es)
BR (1) BRPI0514005A (es)
CA (1) CA2575853C (es)
IL (1) IL181116A0 (es)
MX (1) MX2007001282A (es)
NO (1) NO20070583L (es)
RU (1) RU2420517C2 (es)
TW (1) TW200613272A (es)
UY (1) UY29058A1 (es)
WO (1) WO2006020879A1 (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519754A (ja) * 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006125180A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperazine derivatives and their uses as therapeutic agents
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
JP5031745B2 (ja) * 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
TW200804347A (en) 2006-01-10 2008-01-16 Janssen Pharmaceutica Nv Urotensin II receptor antagonists
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
WO2008008020A1 (en) * 2006-07-12 2008-01-17 Astrazeneca Ab 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents
WO2008012622A2 (en) * 2006-07-25 2008-01-31 Pfizer Products Inc. Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2008012623A1 (en) * 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
CA2659412A1 (en) 2006-07-31 2008-02-07 Janssen Pharmaceutica N.V. Urotensin ii receptor antagonists
ES2627221T3 (es) 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
CA2686651C (en) * 2007-05-25 2015-11-24 Abbott Gmbh & Co. Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
PA8782701A1 (es) * 2007-06-07 2009-01-23 Janssen Pharmaceutica Nv Antagonistas del receptor de urotensina ii
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
EP2205565B1 (en) 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
MX2010005110A (es) 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
TW201000446A (en) * 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
TW201000461A (en) * 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
TW201000462A (en) * 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
TW201000447A (en) * 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
AU2012251943B2 (en) * 2008-06-06 2014-09-25 Astrazeneca Ab Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
JP2011529966A (ja) 2008-08-02 2011-12-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ウロテンシンｉｉ受容体拮抗物質
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
WO2010039545A2 (en) * 2008-09-23 2010-04-08 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
US8563580B2 (en) 2008-09-23 2013-10-22 Georgetown University Flavivirus inhibitors and methods for their use
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
TW201020244A (en) * 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
AU2010234518A1 (en) 2009-04-09 2012-02-02 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
JP2013501006A (ja) 2009-07-31 2013-01-10 コグニション セラピューティクス インク． 認知機能低下の阻害剤
KR20120084306A (ko) * 2009-10-09 2012-07-27 셀진 코포레이션 2-(1-페닐에틸)아이소인돌린-1-온 화합물의 제조 방법
AU2010341573B2 (en) * 2009-12-22 2016-10-13 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
EP2521722B1 (en) * 2010-01-07 2015-05-06 AstraZeneca AB Process for making a metabotropic glutamate receptor positive allosteric modulator - 874
US8664214B2 (en) 2010-03-30 2014-03-04 AbbVie Deutschland GmbH & Co. KG Small molecule potentiators of metabotropic glutamate receptors I
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
EP2603215A4 (en) 2010-08-11 2015-08-05 Philadelphia Health & Educatio NEW DOPAMINERGIC D3 RECEPTOR AGONISTS FOR TREATING DYSKINESIA IN PARKINSON'S DISEASE
US20130203756A1 (en) * 2010-10-29 2013-08-08 Jamie L. Bunda Isoindoline pde10 inhibitors
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
WO2013025897A1 (en) 2011-08-16 2013-02-21 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
TW201321371A (zh) 2011-10-14 2013-06-01 Incyte Corp 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物
CA2853826C (en) 2011-10-28 2021-03-23 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
CN102911109B (zh) * 2012-10-29 2014-01-15 山西医科大学 一种6-氨基-5-氟-1-异吲哚啉酮的制备方法
WO2014077401A1 (ja) * 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
BR112016017808B1 (pt) 2014-01-31 2022-07-12 Cognition Therapeutics, Inc Composto ou sal farmaceuticamente aceitável, uso de um composto e composição para a inibição de um efeito betaamilóide numa célula neuronal
JP6517239B2 (ja) 2014-04-23 2019-05-22 武田薬品工業株式会社 アルツハイマー病治療のためのコリン作動性ムスカリンｍ１受容体ポジティブアロステリックモジュレーター活性としてのイソインドリン−１−オン誘導体
WO2015174534A1 (ja) 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
WO2017075394A1 (en) 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
KR20180070696A (ko) 2015-10-29 2018-06-26 이펙터 테라퓨틱스, 인크. Mnk1 및 mnk2를 억제하는 피롤로-, 피라졸로-, 이미다조-피리미딘 및 피리딘 화합물
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
EA036388B1 (ru) * 2016-03-10 2020-11-03 Астразенека Аб Ингибиторы фосфатидилинозитол-3-киназы гамма
EP3509588B1 (en) * 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
EP3509587B1 (en) 2016-09-12 2023-12-06 Valo Health, Inc. Monocyclic compounds useful as gpr120 modulators
WO2018152117A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
KR102614814B1 (ko) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 신경변성 질환 치료용 조성물
CA3071825A1 (en) * 2017-07-31 2019-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN113286592A (zh) 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
KR20220040291A (ko) * 2020-09-23 2022-03-30 씨엔지바이오 주식회사 4-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
KR20220040294A (ko) * 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
CN115974776A (zh) * 2023-01-19 2023-04-18 利尔化学股份有限公司 一种3,4,5,6-四氯吡啶甲酸的制备方法及其应用
WO2024182692A1 (en) * 2023-03-01 2024-09-06 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE620654C (de) * 1933-04-29 1935-10-24 Smith & Sons Ltd S Geschwindigkeitsanzeiger
US3579524A (en) * 1968-06-05 1971-05-18 Miles Lab 2-aminoalkyl derivatives of phthalimidines
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
WO1992017448A1 (en) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. 3-methyleneisoindolin-1-one derivative
TW219935B (es) * 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
JPH06220044A (ja) * 1991-12-25 1994-08-09 Mitsubishi Kasei Corp ベンズアミド誘導体
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
JP2001524468A (ja) 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
AU2001278508A1 (en) 2000-07-31 2002-02-13 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor
JP4529119B2 (ja) 2001-08-09 2010-08-25 小野薬品工業株式会社 カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
US7087601B2 (en) * 2001-11-30 2006-08-08 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US20040242572A1 (en) * 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
EP1611096A4 (en) 2003-03-26 2007-08-29 Merck & Co Inc BENZAMIDE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
JP2007510629A (ja) 2003-10-22 2007-04-26 イーライ リリー アンド カンパニー 新規ｍｃｈ受容体アンタゴニスト
JP2007519754A (ja) * 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
AU2005219791B2 (en) * 2004-03-05 2011-06-09 Msd K.K. Diaryl-substituted five-membered heterocycle derivative
DK1731512T3 (en) 2004-03-05 2015-01-05 Nissan Chemical Ind Ltd Isoxazoline-substituted benzamide AND INSTRUMENTS FOR COMBATING HARMFUL ORGANISMS
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators

Also Published As

Publication number Publication date
KR20130082183A (ko) 2013-07-18
JP2012180364A (ja) 2012-09-20
NO20070583L (no) 2007-03-08
CN102134214A (zh) 2011-07-27
CN102134214B (zh) 2013-05-22
EP2357169A1 (en) 2011-08-17
US20090275578A1 (en) 2009-11-05
JP5658195B2 (ja) 2015-01-21
IL181116A0 (en) 2007-07-04
UY29058A1 (es) 2006-02-24
KR20140116208A (ko) 2014-10-01
KR101477553B1 (ko) 2014-12-30
AU2005272738B2 (en) 2012-04-05
JP2008509926A (ja) 2008-04-03
MX2007001282A (es) 2007-04-18
RU2420517C2 (ru) 2011-06-10
RU2007103769A (ru) 2008-09-20
US7968570B2 (en) 2011-06-28
CA2575853A1 (en) 2006-02-23
KR20070097405A (ko) 2007-10-04
TW200613272A (en) 2006-05-01
AU2005272738A1 (en) 2006-02-23
BRPI0514005A (pt) 2008-05-27
EP1778634A1 (en) 2007-05-02
JP5031565B2 (ja) 2012-09-19
WO2006020879A1 (en) 2006-02-23
CA2575853C (en) 2014-09-23
CN101039907B (zh) 2011-02-23
CN101039907A (zh) 2007-09-19

Similar Documents

Publication Publication Date Title
AR050691A1 (es) Compuestos de isoindolona como potenciadores del receptor metabotropico de glutamato. procesos de obtencion y composiciones farmaceuticas.
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR054789A1 (es) Antagonistas del receptor 1 de triazolopiridina canabinoide
PE20091429A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne)
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
AR076098A1 (es) Derivados de benzofurano
PE20161400A1 (es) Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
PE20140961A1 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
AR059249A1 (es) Compuesto amina trisustituido
AR054814A1 (es) Derivados de piridazina
AR054365A1 (es) Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
RU2403250C2 (ru) Производные пиперидин-4-иламида и их применение в качестве антагонистов рецептора sst подтипа 5
PE20050157A1 (es) Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar)
UY25904A1 (es) Sulfonamidas heterocíclicas inhibidoras de receptores de endotelina
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
PE20060977A1 (es) Derivados de piperidinilo como bloqueantes de canales de calcio
AR066561A1 (es) Derivados de imidazol, composiciones farmaceuticas y usos
JP2012520238A5 (es)
AR045602A1 (es) Derivados de benzoilpiperazinas, procesos de obtencion y composiciones farmaceuticas.
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
AR055041A1 (es) Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
AR055171A1 (es) Derivados de carboxamida como antagonistas del receptor muscarinico
AR057728A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotropicos. composiciones farmaceuticas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure